Bavarian Nordic to Acquire Emergent BioSolutions’ Vivotif, Vaxchora and an Under Developed Chikungunya Vaccine
Shots:
- Through an agreement with Emergent BioSolutions, Bavarian Nordic acquired Vivotif and Vaxchora vaccines approved for typhoid fever and cholera respectively, and a vaccine for chikungunya which is ongoing in P-III clinical trial
- Under the terms of the acquisition, Emergent will receive an upfront payment of ~$270M and conditional milestones payment of ~$110M on the development ($80M) and sales ($30M) of the chikungunya vaccine. The transaction is expected to be closed in H1’23
- Both products are commercialized in >25 countries along the US and the EU. The data from the ongoing P-III study is expected in H2’23 along with a commercial launch in 2025
Ref: Globe Newswire | Image: Bavarian Nordic
Related News:- Bavarian Nordic Reports the First Patient Dosing in P-III (VANIR) Trial for the Treatment of Respiratory Syncytial Virus
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
